Literature DB >> 24740077

Determining the optimal ceftriaxone MIC for triggering extended-spectrum β-lactamase confirmatory testing.

Yanjie Huang1, Karen C Carroll2, Sara E Cosgrove3, Pranita D Tamma4.   

Abstract

As routine testing of clinical isolates for extended-spectrum β-lactamase (ESBL) production (screen plus phenotypic confirmatory testing) is no longer required by the Clinical and Laboratory Standards Institute (CLSI), a number of clinical microbiology laboratories use ceftriaxone MICs as a proxy means of identifying bacteria as potential ESBL producers. Data from 1,386 clinical isolates suggest that a ceftriaxone MIC cutoff of 8 μg/ml is an excellent predictor of ESBL production, with a positive predictive value and negative predictive value approaching 100% and 99.5%, respectively.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24740077      PMCID： PMC4042788          DOI： 10.1128/JCM.00716-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  10 in total

1.  Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria?

Authors:  Federico Perez; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2011-11-04       Impact factor: 9.079

2.  Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests.

Authors:  Dror Marchaim; Bharath Sunkara; Paul R Lephart; Uma Mahesh Gudur; Ashish Bhargava; Ryan P Mynatt; Jing J Zhao; Suchitha Bheemreddy; Kayoko Hayakawa; Teena Chopra; Sorabh Dhar; Keith S Kaye
Journal:  Infect Control Hosp Epidemiol       Date:  2012-06-11       Impact factor: 3.254

3.  An outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit.

Authors:  Pranita D Tamma; Patrice Savard; Tibor Pál; Ágnes Sonnevend; Trish M Perl; Aaron M Milstone
Journal:  Infect Control Hosp Epidemiol       Date:  2012-04-16       Impact factor: 3.254

4.  Do patient data really support the clinical and laboratory standards institute recommendation for lowering third-generation cephalosporin interpretive breakpoints?

Authors:  Pranita D Tamma; John H Powers
Journal:  Clin Infect Dis       Date:  2013-05-08       Impact factor: 9.079

Review 5.  Treatment of multidrug-resistant Gram-negative infections in children.

Authors:  Alice J Hsu; Pranita D Tamma
Journal:  Clin Infect Dis       Date:  2014-02-05       Impact factor: 9.079

6.  Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions.

Authors:  Jesús Oteo; Carmen Navarro; Emilia Cercenado; Alberto Delgado-Iribarren; Isabel Wilhelmi; Beatriz Orden; Carmen García; Silvia Miguelañez; María Pérez-Vázquez; Silvia García-Cobos; Belén Aracil; Verónica Bautista; José Campos
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

7.  Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.

Authors:  Nan-Yao Lee; Ching-Chi Lee; Wei-Han Huang; Ko-Chung Tsui; Po-Ren Hsueh; Wen-Chien Ko
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

8.  Outcomes of children with enterobacteriaceae bacteremia with reduced susceptibility to ceftriaxone: do the revised breakpoints translate to improved patient outcomes?

Authors:  Pranita D Tamma; Harold Wu; Jeffrey S Gerber; Alice J Hsu; Tsigereda Tekle; Karen C Carroll; Sara E Cosgrove
Journal:  Pediatr Infect Dis J       Date:  2013-09       Impact factor: 2.129

Review 9.  Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

Authors:  Michael N Dudley; Paul G Ambrose; Sujata M Bhavnani; William A Craig; Mary Jane Ferraro; Ronald N Jones
Journal:  Clin Infect Dis       Date:  2013-01-18       Impact factor: 9.079

10.  The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae.

Authors:  Pranita D Tamma; Sonya C T Girdwood; Ravindra Gopaul; Tsigereda Tekle; Ava A Roberts; Anthony D Harris; Sara E Cosgrove; Karen C Carroll
Journal:  Clin Infect Dis       Date:  2013-06-11       Impact factor: 9.079
  10 in total
  9 in total

Review 1.  Point-Counterpoint: Piperacillin-Tazobactam Should Be Used To Treat Infections with Extended-Spectrum-Beta-Lactamase-Positive Organisms.

Authors:  Audrey N Schuetz; Sergio Reyes; Pranita D Tamma
Journal:  J Clin Microbiol       Date:  2018-02-22       Impact factor: 5.948

2.  Synergism between WLBU2 peptide and antibiotics against methicillin-resistant Staphylococcus aureus and extended-spectrum beta-lactamase-producing Enterobacter cloacae.

Authors:  Lina Elsalem; Suhaila Al Sheboul; Ayat Khasawneh
Journal:  J Appl Biomed       Date:  2021-01-18       Impact factor: 1.797

3.  Short- and long-term mortality in patients with urosepsis caused by Escherichia coli susceptible and resistant to 3rd generation cephalosporins.

Authors:  Milena Tocut; Iris Zohar; Orna Schwartz; Orit Yossepowitch; Yasmin Maor
Journal:  BMC Infect Dis       Date:  2022-06-24       Impact factor: 3.667

4.  Risk Factors for Extended-Spectrum β-lactamase-Producing Enterobacterales Bloodstream Infection Among Solid-Organ Transplant Recipients.

Authors:  Judith A Anesi; Ebbing Lautenbach; Pranita D Tamma; Kerri A Thom; Emily A Blumberg; Kevin Alby; Warren B Bilker; Alissa Werzen; Pam Tolomeo; Jacqueline Omorogbe; Lisa Pineles; Jennifer H Han
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

5.  Fluoroquinolone-Resistant and Extended-Spectrum β-Lactamase-Producing Escherichia coli Infections in Patients with Pyelonephritis, United States(1).

Authors:  David A Talan; Sukhjit S Takhar; Anusha Krishnadasan; Fredrick M Abrahamian; William R Mower; Gregory J Moran
Journal:  Emerg Infect Dis       Date:  2016-09       Impact factor: 6.883

6.  Dosing of Ceftriaxone and Metronidazole for Children With Severe Acute Malnutrition.

Authors:  Joseph F Standing; Martin O Ongas; Caroline Ogwang; Nancy Kagwanja; Sheila Murunga; Shalton Mwaringa; Rehema Ali; Neema Mturi; Moline Timbwa; Christine Manyasi; Laura Mwalekwa; Victor L Bandika; Bernhards Ogutu; Joseph Waichungo; Karin Kipper; James A Berkley
Journal:  Clin Pharmacol Ther       Date:  2018-04-19       Impact factor: 6.875

Review 7.  Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection.

Authors:  Mariana Castanheira; Patricia J Simner; Patricia A Bradford
Journal:  JAC Antimicrob Resist       Date:  2021-07-16

8.  Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?

Authors:  Pranita D Tamma; Virginia M Pierce; Sara E Cosgrove; Ebbing Lautenbach; Anthony Harris; Divya Rayapati; Jennifer H Han
Journal:  Open Forum Infect Dis       Date:  2018-06-08       Impact factor: 3.835

9.  Effect of antibiotic stewardship interventions in primary care on antimicrobial resistance of Escherichia coli bacteraemia in England (2013-18): a quasi-experimental, ecological, data linkage study.

Authors:  Shirin Aliabadi; Philip Anyanwu; Elizabeth Beech; Elita Jauneikaite; Peter Wilson; Russell Hope; Azeem Majeed; Berit Muller-Pebody; Céire Costelloe
Journal:  Lancet Infect Dis       Date:  2021-08-04       Impact factor: 25.071
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.